Saturday, October 15, 2022 from 3:30 PM to 5:00 PM PDT at Imperial Ballroom A
Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-22-155-L01-P
Activity Type: An Application-Based Activity
This session focused on updates in medication use in liver disease focusing on the application of recent literature and practice guidelines to determine the appropriate use of albumin and proton pump inhibitors in patients with cirrhosis. Specific topics will include 1) a debate-style discussion on the place in therapy of albumin in the treatment of complications of cirrhosis and 2) the use of proton pump inhibitors (PPIs), including general use based on pharmacokinetic changes seen in liver disease and risk of complications in patients with cirrhosis. The target audience of this session is pharmacy personnel that practice in an inpatient non-ICU setting (i.e. internal medicine, family medicine, etc.) or in an ambulatory care/ community setting. The purpose of this session is to update adult medicine and hepatology/gastroenterology practitioners on current best practices in managing medications in patients with cirrhosis with various complications.
 | Moderator: Kelsey M. Rife, Pharm.D., BCACP
Gastroenterology/Hepatology Clinical Pharmacist, VA Northeast Ohio Healthcare System;
Clinical Program Manager – Academic Affairs, VA Northeast Ohio Healthcare System
Cleveland, Ohio
View Biography |
Learning Objectives
1. Debate the use of long-term albumin infusion in cirrhosis and ascites.
2. Evaluate recent literature on the use of albumin in hospitalized patients with decompensated cirrhosis.
3. Debate the use of albumin for hyponatremia in hospitalized patients with cirrhosis.
4. Assess patients for complications of cirrhosis associated with the use of proton pump inhibitors.
5. Recommend an appropriate proton pump inhibitor regimen for use in a patient with cirrhosis.